At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 77 enrolled
Drug / intervention
Ruxolitinib cream +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis Involvement
In Brief
A Phase 2 clinical trial evaluating Ruxolitinib cream and Vehicle for Atopic Dermatitis. Completed, enrolled 77 participants across 1 site.
Detailed Summary
This is a randomized, double blind, vehicle controlled Phase 2 study with a 4-week open label extension in adolescent and adult participants with atopic dermatitis and head and/or neck involvement. It is intended to compare the efficacy and safety of ruxolitinib cream 1.5% BID versus vehicle cream, then further evaluate ruxolitinib cream as maintenance during the open label extension period.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
Enrollment StartNov 2021
First PostedNov 2021
Primary CompletionAug 2023
Study CompletionSep 2023
TodayJul 2026
First PostedNov 19, 2021
Enrollment StartNov 10, 2021
Primary CompletionAug 3, 2023
Study CompletionSep 29, 2023
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 4.6 years ago
Interventions
Ruxolitinib creamdrug
Ruxolitinib cream 1.5% applied twice a day (BID)"
Vehicledrug
Vehicle cream applied twice a day (BID) to affected areas